Nutritional High Provides Update on Its California Subsidiar TORONTO, April 05, 2018 (GLOBE NEWSWIRE) -- Nutritional High International Inc. (the “Company” or “Nutritional High”) (CSE:EAT)(OTCQB:SPLIF)(FRANKFURT:2NU) is pleased to provide an operational update on its subsidiary Calyx Brands, Inc. (“Calyx”). Calyx is a leading distributor of cannabis products throughout California and the Company closed its acquisition of Calyx in March of 2018 (see press release dated March 16, 2018).
Sale of FLI Vaporizer Cartridges to Prominent Cannabis Product Membership Service
Calyx recently completed an initial sale of FLI vape cartridges to ClubM, a prominent membership-based service that provides a curated list of California’s premier cannabis products to customers.
New Distribution Agreements Signed
Calyx has signed distribution agreements with 2 exciting cannabis brands, Vive and Euphorix, and is in the process of integrating these product offerings into their distribution network. Vive produces a line of cannabis-infused micro-dosing tablets, in a range of flavors with ratios ranging from 1mg to 5mg THC, pure CBD and CBD-ratio options. Micro-dosing is a growing trend as the number of first-time users increase, and Vive’s discreet, low THC products target these customer segments. Euphorix currently sells non-cannabis infused cannabis-free beverages across the U.S. and its cannabis-infused beverages are being launched in California.
Expansion of Distribution Relationship with Plus Products
Calyx has expanded its relationship with Plus Products and will be responsible for distributing the Plus suite of products to Eaze, the largest delivery platform in California. Plus offers a range of cannabis-infused gummy products with Indica, Sativa, and Hybrid-based offerings. This development has the potential to greatly expand Calyx’s profile within the California cannabis market.
Dakota Sullivan, CEO of Calyx, commented, "We are proud to be sharing these developments and look forward to continuing to build our distribution platform in California. These developments will enhance our ability to service both the medical and adult-use markets under the Nutritional High banner and further develop the company’s retail strategy in the state."
Jim Frazier, CEO of Nutritional High, added, "We are very excited to share these developments with our shareholders and look forward to the expanded profile we believe will drive revenue for Calyx. The California market is a key aspect of our corporate strategy and we look forward to continuing to develop our footprint there through Calyx and other avenues.”
About Nutritional High International Inc.
Nutritional High is focused on developing, manufacturing and distributing premium and consistently dosed products in the cannabis-infused products industry, including edibles and oil extracts for nutritional, medical and adult recreational use. The Company works exclusively through licensed facilities in jurisdictions where such activity is permitted and regulated by state law.
For updates on the Company’s activities and highlights of the Company’s press releases and other media coverage, please follow Nutritional High on Facebook, Twitter and Instagram or visit www.nutritionalhigh.com.
For further information, please contact:
David Posner
Chairman of the Board
Nutritional High International Inc.
647-985-6727
Email: dposner@nutritionalhigh.com
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR OTC MARKETS GROUP INC., NOR THEIR REGULATIONS SERVICES PROVIDERS HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Risks that may have an impact on the ability for these events to be achieved include completion of due diligence, negotiation of definitive agreements and receipt of applicable approvals. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.
The Company’s securities have not been registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or “U.S. Persons”, as such term is defined in Regulation S under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful.
Additionally, there are known and unknown risk factors which could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law. Some of the risks and other factors that could cause actual results to differ materially from those expressed in forward-looking information expressed in this press release include, but are not limited to: obtaining and maintaining regulatory approvals including acquiring and renewing U.S. state, local or other licenses, the uncertainty of existing protection from U.S. federal or other prosecution, regulatory or political change such as changes in applicable laws and regulations, including U.S. state-law legalization, market and general economic conditions of the cannabis sector or otherwise.